(1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamid e (PPDC), a new class of NMDA-receptor antagonist: Molecular design by a novel conformational restriction strategy

Japanese Journal of Pharmacology

Volumn 85, Issue 3, 2001, Pages 207-213

  Shuto, S ^a   Yoshii, K ^a   Matsuda, A ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

(1S,2R) 1 phenyl 2 (S) 1 aminopropyl N,N diethylcyclopropanecarboxami de (PPDC); Conformationally restricted analog; Cyclopropane; Milnacipran; NMDA receptor

Indexed keywords

1 PHENYL 2 [1 AMINOPROPYL] N,N DIETHYLCYCLOPROPANECARBOXAMIDE; 2 AMINO 5 PHOSPHONOVALERIC ACID; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; GLUTAMATE RECEPTOR; KETAMINE; LEVODOPA; MESSENGER RNA; MILNACIPRAN; MUSCARINIC M1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN; PHENCYCLIDINE; RECEPTOR SUBUNIT; SEROTONIN; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING SITE; BRAIN CORTEX; CELL DEATH; DISEASE MODEL; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; METABOLIC INHIBITION; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMITTER UPTAKE; NONHUMAN; NORADRENALIN RELEASE; NUCLEAR OVERHAUSER EFFECT; OOCYTE; PARKINSON DISEASE; RECEPTOR AFFINITY; REVIEW; SEROTONIN UPTAKE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VOLTAGE CLAMP; XENOPUS;

EID: 0035067822     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.85.207     Document Type: Review

References (31)

1. The glutamate receptor ion channels
2. Ligands for glutamate receptor: Design and therapeutic prospects
3. Actions of D- and L-forms of 2-amino-5-phosphnvalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord
4. Synthesis and NMDA antagonists properties of the enantiomers of 4-(3-phosphonopropyl)piperazine-2-carboxylic acid (CPP) and the unsaturated analogue (E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (CPP-ene)
5. 6-Substitutued dehydroisoquinoline-3-carboxylic acids as potent and selective conformationally constained NMDA antagonists
6. The dissociative anaesthesics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-D-aspartate
7. Quantitative studies on some antagonists of NMDA in slices of rat cerebral cortex
8. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: Selective binding to open channels
9. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist
10. The behavioral pharmacology of NMDA receptor antagonist
11. The behavioral effects of MK-801: A comparison with antagonists acting non-competitively at the NMDA receptor
12. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
13. A comparison of the anticonvulsant potency of (±)-2-amino-5-phosphonopentanoic acid and (±)-2-amino-7-phosphonoheptanoic acid
14. In vivo distribution of CGS-19755 within brain in a model of focal cerebral ischemia
15. 4-Amino-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor
16. Novel systematically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: Electrophysiological biochemical and behavioral characterization
17. Selective serotonin/noradrenaline re-uptake inhibitors (SNRIs). Pharmacology and therapeutic potential in the treatment of depressive disorders
18. (±)-(Z)-2-Aminomethyl-1-phenylcyclopropanecarboxamide derivates as a new prototype of NMDA receptor antagonists
19. Conformational restriction by repulsion between adjacent substituents of a cyclopropane ring: Design and enantioselective syntehesis of 1-phenyl-2-(1-aminoalkyl)-N,N-diethylcyclopropanecarboxamides as potent NMDA receptor antagonists
20. Synthesis of (+)- and (-)-milnaciprans and their confomationally restricted analogs
21. Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,1R)-1-Phenyl-2[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist
22. Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-Phenyl-2-[(R)-1-amino-2-propynyl]-N,N-diethylcyclopropanecarboxamide is a novel class of NMDA receptor channel blocker
23. Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and their protective effect against NMDA-induced neurotoxicity
24. A new method for conformational restriction based on repulsion between adjacent substituents on a cyclopropane ring and its application to the development of potent N-methyl-D-aspartic acid (NMDA) receptor antagonists
25. Highly steroselective addition of Grignard reagents to C-cyclopropylnitrone via the bisected s-trans conformation. An efficient synthesis of 1-phenyl-2-[(S)-1-aminoalkyl]-N,N-diethylcyclopropanecarboxamides, a new class of potent NMDA receptor antagonists
26. 2+ of NMDA responses in spinal cord neurons
27. High probability opening of NMDA receptor channels by L-glutamate
28. Subtype-selective N-methyl-D-aspartate receptor antagonists: Benzimidazolone and hydantoin as phenol replacements
29. Structure and function of the NMDA receptor channel
30. Pharmacological heterogeneity of NMDA receptors: Characterization of NR1a/NR2D heteromers expressed in Xenopus oocytes